Dr. McFarland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 S Park St
Madison, WI 53715Phone+1 608-287-2552Fax+1 608-287-2781
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993- Tufts Medical CenterResidency, Internal Medicine, 1987 - 1990
University of Illinois College of MedicineClass of 1987
Certifications & Licensure
IL State Medical License 2017 - 2026
WI State Medical License 1994 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Start of enrollment: 2014 Jun 13
Publications & Presentations
PubMed
- 11 citationsPhase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanomaMark R. Albertini, Erik A. Ranheim, Cindy L. Zuleger, Paul M. Sondel, Jacquelyn A. Hank
Cancer Immunology, Immunotherapy. 2016-05-20 - 45 citationsVcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network studyJulie E. Chang, Christopher Peterson, Sangbum Choi, Jens C. Eickhoff, KyungMann Kim
British Journal of Haematology. 2011-10-01 - 19 citationsA phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.Mark Agulnik, Ricardo Costa, Mohammed M. Milhem, Alfred Rademaker, B. C. Prunder
Annals of Oncology. 2017-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
